Antiviral İlaç Zehirlenmeleri
Özet
Bu çalışma, virüslerin biyolojik yapılarını, replikasyon aşamalarını ve bu aşamalara müdahale eden antiviral ilaçların toksisite profilleri ile zehirlenme yönetimi stratejilerini kapsamlı bir şekilde incelemektedir. Antiviral ajanlar genel olarak antiherpes ilaçlar, antiinfluenza ilaçlar, antiretroviral ajanlar (NRTI, NNRTI, proteaz inhibitörleri ve füzyon inhibitörleri) ile ribavirin ve adefovir gibi diğer antiviral ilaçlar olarak sınıflandırılır. Antiherpes grubunda yer alan asiklovir, sidofovir, gansiklovir ve famsiklovir gibi ilaçlar temel olarak nefrotoksisite, kristalüri ve nörotoksisiteye yol açabilir; bu tür intoksikasyon vakalarında gastrik lavaj, aktif kömür, iv hidrasyon ve hemodiyaliz gibi destekleyici müdahaleler uygulanır. Antiinfluenza ilaçlarından M2 inhibitörü amantadin merkezi sinir sistemi ile kardiyovasküler sistem üzerinde şiddetli antikolinerjik etkilere ve nöbetlere neden olabilirken, nöraminidaz inhibitörleri olan oseltamivir ve zanamivir genellikle iyi tolere edilir. Antiretroviral ilaç grubundaki NRTI'lar en ciddi yan etki olarak yüksek mortaliteye sahip laktik asidemi, miyelosupresyon ve pankreatite sebep olabilir; NNRTI'lar karaciğer disfonksiyonu ve Steven-Johnson sendromuna, proteaz inhibitörleri ise lipodistrofi ve sindirim sistemi bozukluklarına yol açabilir. Diğer yandan ribavirin kullanımı ciddi hemolitik anemi tablosu üretebilir. Sonuç itibarıyla, antiviral ilaçların geniş terapötik doz aralıkları nedeniyle zehirlenme vakaları nadir görülse de, bu toksik profillerin doğru tanınması ve gerektiğinde hastaların daha güvenli alternatif tedavilere yönlendirilmesi büyük önem arz etmektedir.
This study comprehensively examines the biological structures of viruses, their replication stages, and the toxicity profiles and poisoning management strategies of antiviral drugs that intervene in these stages. Antiviral agents are generally classified as antiherpes drugs, antiinfluenza drugs, antiretroviral agents (NRTIs, NNRTIs, protease inhibitors, and fusion inhibitors), and other antiviral drugs such as ribavirin and adefovir. Drugs in the antiherpes group, such as acyclovir, cidofovir, ganciclovir, and famciclovir, can primarily cause nephrotoxicity, crystalluria, and neurotoxicity; in such cases of intoxication, supportive interventions like gastric lavage, activated charcoal, IV hydration, and hemodialysis are administered. Among antiinfluenza drugs, the M2 inhibitor amantadine can cause severe anticholinergic effects and seizures on the central nervous system and cardiovascular system, whereas neuraminidase inhibitors oseltamivir and zanamivir are generally well tolerated. Among antiretroviral drugs, NRTIs can cause lactic acidemia with high mortality, myelosuppression, and pancreatitis as the most severe adverse effects; NNRTIs can cause hepatic dysfunction and Stevens-Johnson syndrome, while protease inhibitors can lead to lipodystrophy and digestive system disorders. On the other hand, ribavirin use can result in severe hemolytic anemia. Consequently, although poisoning cases are rare due to the wide therapeutic dose ranges of antiviral drugs, correctly recognizing these toxic profiles and directing patients to safer alternative treatments when necessary is of great importance.
Referanslar
Wang, F. & Kieff, E. (2018). Medical Virology. In D. L. Kasper, A. S. Fauci, S. L. Hauser, D. L. Longo, J. L. Jameson & J. Loscalzo (Eds), Harrison’s Principles of Internal Medicine (20th ed., p. 1325-1333). New York: McGraw Hill.
Acosta, E. P. & Flexner, C. (2018). Antiviral agents. In L. L. Brunton (Ed.), Goodman & Gilman’s The Pharmacology Basis of Theraputics (13th ed., pp.1105-1118). New York: McGraw Hill.
Kumar, S. (2012). General properties of viruses. In S. Kumar (Ed.), Textbook of Microbiology (1st ed., pp. 503-517). New Delhi: Jaypee Brothers Medıcal.
Hilal-Dandan, R. & Brunton, L. L. (2014). Goodman & Gilman’s Manual of Pharmacology and Therapeutics (2nd Ed.). Philadelphia: McGraw Hill.
Leikin, J. B. & Paloucek, F. P. (2008). Poisoning and Toxicology Handbook (4th ed.). New York: Informa Healthcare
Ratanajamit C, Vinther Skriver M, et al. Adverse pregnancy outcome in women exposed to acyclovir during pregnancy: a population-based observational study. Scand J Infect Dis, 2003;35(4):255-259. Doi:10.1080/00365540310000229
Hsu CC, Lai TI, Lien WC, et al. Emergent hemodialysis for acyclovir toxicity. Am J Emerg Med, 2005;23(7):899-900. Doi:10.1016/j.ajem.2005.04.012
Britt WJ, Prichard MN. New therapies for human cytomegalovirus infections. Antiviral Res. 2018;159:153-174. Doi:10.1016/j.antiviral.2018.09.003
MacDougall, C. (2018). Antiviral and antiretroviral agents. In K. R. Olson (Ed.), Poisoning and drug overdose (7th ed.). California: McGraw Hill.
Ekmekyapar M, Gürbüz Ş. Antiviral drugs and their toxicities. Eurasian Journal of Toxicology. 2019; 1(3): 77-84.
Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother, 2000;44:2811-5.
Ison MG, Hayden FG. Therapeutic options for the management of influenza. Curr Opin Pharmacol. 2001;1(5):482-490. Doi:10.1016/s1471-4892(01)00084-4
European Medicines Agency. Summary Report: Review on influenza antiviral medicinal products for potential use during pandemic. EMEA/CHMP 2005; London,1-18.
Keyser LA, Karl M, Nafziger AN, et al. Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of ınfluenza a in elderly nursing home patients. Arch Intern Med. 2000;160(10):1485–1488. Doi:10.1001/archinte.160.10.1485
DeWitt C, Heard K, Dart RC. CNS and CV effects in acute amantadine overdoses in children. J Toxicol Clin Toxicol. 2004;42(5):713-816. Doi: 10.1081/CLT-200026959
Michalski LS, Hantsch CE, Hou SH. Amantadine toxicity in a renal transplant patient. J Toxicol Clin Toxicol, 2003;41(5):641-752. Doi: 10.1081=CLT-120024368
Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet. 2000;355(9206):827-835. Doi:10.1016/S0140-6736(99)11433-8
Ohuchi M, Asaoka N, Sakai T, et al. Roles of neuraminidase in the initial stage of influenza virus infection. Microbes Infect, 2006;8(5):1287-1293. Doi:10.1016/j.micinf.2005.12.008
Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet, 2004;364(9436):759-765. Doi:10.1016/S0140-6736(04)16934-1
Piacenti FJ. An update and review of antiretroviral therapy. Pharmacotherapy, 2006;26(8):1111-1133. Doi:10.1592/phco.26.8.1111
Falco V, Rodriguez D, Ribera E, et al. Severe nucleoside-associated lactic acidosiss in human immunodeficiency virus-infected patients. Report of 12 cases and review of the literature Clin Infect Dis, 2002;34:838-846. Doi: 10.1086/339041
Stork, C. M. (2019). Antimicrobials, Antifungals, and Antivirals. In L. S. Nelson, N. A. Lewin, M. A. Howland, S. V. Smith, R. S. Hoffman, L. R. Goldfrank & N. E. Flomenbaum (Eds), Goldfrank’s Toxicologic Emergencies (11th ed., pp. 821-835). New York: McGraw Hill.
Kirian MA, Higginson RT, Fulco PP. Acute onset of pancreatitis with concomitant use of tenofovir and didanosine. Ann Pharmacother, 2004;38(10):1660-1663. doi:10.1345/aph.1D616
Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management. Drug Saf, 1998;19(6):481-494. doi:10.2165/00002018-199819060-00005
Harris M, Montaner JS. Clinical uses of non-nucleoside reverse transcriptase inhibitors. Rev Med Virol, 2000;10(4):217-229. Doi:10.1002/1099-1654(200007/08)10:4<217::aid-rmv279>3.0.co;2-l
Flexner C. HIV-protease inhibitors. N Engl J Med, 1998;338(18):1281-1292. Doi:10.1056/NEJM199804303381808
Dando TM, Perry CM. Enfuvirtide. Drugs, 2003;63(24):2755-2768. Doi:10.2165/00003495-200363240-00005